ADIL (Adial Pharmaceuticals, Inc) Stock Analysis - News
Adial Pharmaceuticals, Inc (ADIL) is a publicly traded Healthcare sector company. As of May 21, 2026, ADIL trades at $2.36 with a market cap of $3.45M and a P/E ratio of -0.19. ADIL moved +14.08% today. Year to date, ADIL is -63.15%; over the trailing twelve months it is -87.06%. Its 52-week range spans $1.31 to $32.50. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ADIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ADIL news today?
FDA Flexibility Could Cut AD04 Costs; Company Holds $4.6M, Eyes Europe: FDA policy may allow approval based on one pivotal study plus confirmatory evidence, potentially cutting Phase 3 costs and accelerating AD04’s NDA timeline. The company held $4.6M cash at March 31, funding operations into H2 2026 and set a Molteni Farmaceutici collaboration in Europe.
FDA Flexibility Could Cut AD04 Costs; Company Holds $4.6M, Eyes Europe: FDA policy may allow approval based on one pivotal study plus confirmatory evidence, potentially cutting Phase 3 costs and accelerating AD04’s NDA timeline. The company held $4.6M cash at March 31, funding operations into H2 2026 and set a Molteni Farmaceutici collaboration in Europe.
Does Rallies summarize ADIL news?
Yes. Rallies summarizes ADIL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ADIL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ADIL. It does not provide personalized investment advice.
